Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “130 mg administered by intravenous injection over 30 seconds, followed by a 10 mL normal saline flush administered intravenously over 30 seconds. A subset of participants will receive two doses of MB-102, 12 hours apart.”In the company’s words, NCT02772276 on ClinicalTrials.gov
- Tested for
- Acute Kidney Injury
- Main trialPhase 2
- “This study was a pilot, safety, and pharmacokinetic study of MB-102 versus iohexol and the use of the non-invasive optical renal function monitor (ORFM) device in normal and compromised renal function participants with different skin color types.”In the company’s words, NCT02772276 on ClinicalTrials.gov
- Other names
- Relmapirazin
Other drugs for Acute Kidney Injury
- QRX-3Ebima Clifford Okundaye · Phase 2/3
- PrismocitrateVantive Health LLC · Phase 3
- AZD4144AstraZeneca · Phase 2
- LSALT peptideArch Biopartners Inc. · Phase 2
- R2R01River 2 Renal Corp. · Phase 2
- CSL889CSL Behring · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 4 Aug 2021 | Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026